Sun Pharmaceutical Industries Limited

NSE: SUNPHARMA · Healthcare · Lot size: 350

OverviewOption ChainOI AnalysisFII / DIIMax Pain

Sun Pharmaceutical Industries Limited Share Price & Analysis

₹1,783.1Updated 5 Jun 2026, 03:30 pm IST
LTP
₹1,783.1
—
Open
₹1,789
High
₹1,802.9
Low
₹1,779
Close
₹1,780.1
52W High
₹1,917
52W Low
₹1,547
Volume
2495K
Lot Size
350
Sector
Healthcare
Market Cap
₹4.3L Cr
Face Value
₹1
Large CapNIFTY 100NIFTY 200NIFTY 50NIFTY 500

Price Chart

Fundamentals

P/E
34.4
Sector P/E
48.9
P/B
5.12
EPS
₹45.5
ROE
16%
ROCE
20.5%
D/E Ratio
0.06
Div Yield
0.89%
Book Value
₹348
+

Strengths

  • ✓Strong return on equity (ROE 16%)
  • ✓Efficient capital deployment (ROCE 20.5%)
  • ✓Attractively valued vs sector (P/E 34.4x vs industry 48.9x)
  • ✓Virtually debt-free

Peer Comparison

CompanyCMPMkt CapP/EP/BROE %ROCE %D/E
DIVISLAB
Divi's Laboratories Limited
₹6,616
₹1.7L Cr66.110.4816.5220.01
TORNTPHARM
Torrent Pharmaceuticals Limited
₹4,416
₹1.5L Cr66.417.8127.615.40.33
APOLLOHOSP
Apollo Hospitals Enterprise Limited
₹8,315
₹1.2L Cr59.512.6222.117.90.88
CIPLA
Cipla Limited
₹1,402
₹1.1L Cr27.33.2912.416.60.01
ZYDUSLIFE
Zydus Lifesciences Limited
₹1,091
₹1.1L Cr204.0521.221.20.38
DRREDDY
Dr. Reddy's Laboratories Limited
₹1,283
₹1.1L Cr25.42.8311.813.60.16
LUPIN
Lupin Limited
₹2,260
₹1.0L Cr17.94.629.130.30.32

Showing 7 peers in the same sector · Sorted by market cap

Shareholding Pattern

SUNPHARMA · as of Mar 2026

Promoters54.48%
FII17.96%▼0.08
DII18.58%▲0.15
Public8.86%▼0.06
Govt0.11%
CategoryDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters54.48%54.48%54.48%54.48%54.48%54.48%
FII17.08%17.72%17.23%18.01%18.04%17.96%
DII19.42%18.71%19.17%18.48%18.43%18.58%
Public8.92%8.97%9.00%8.89%8.92%8.86%
Govt0.11%0.11%0.11%0.11%0.11%0.11%

Corporate Events

To consider and approve the Audited Standalone and Consolidated Financial Results for the quarter and year ended 31 March 2026 and recommendation of final dividend for FY 2025-26

Dividend21 May 2026

Interim Dividend - Rs 11 Per Share

Dividend4 Feb 2026

Dividend - Rs 5.50 Per Share

Dividend6 Jul 2025

Interim Dividend - Rs 10.50 Per Share

Dividend5 Feb 2025

Dividend - Rs 5 Per Share

Dividend11 Jul 2024

Interim Dividend - Rs 8.50 Per Share

Dividend8 Feb 2024

Dividend - Rs 4 Per Share

Dividend27 Jul 2023

Latest News

All news →

Sun Pharma, Coforge eye overseas acquisitions amid weak domestic growth

*Sun Pharma, Coforge eye overseas acquisitions amid weak domestic growth* — Indian firms are targeting foreign buys as home market growth slows. Sun Pharma and Coforge are actively exploring international deals to diversify revenue. These strategic moves aim to leverage global opportunities while domestic demand remains subdued. 📊 *STOCKS:* SUNPHARMA, COFORGE | 🏢 *SECTOR:* Corporate | #MEDIUMIMPACT #Acquisition

BBC25 May
Medium Impact

Sun Pharma confirms cyber attack, 17TB data breached

*Sun Pharma confirms cyber attack, 17TB data breached.* Hackers accessed **17TB of sensitive data**, disrupting operations and raising concerns over IP security. The company is assessing damage and may face regulatory scrutiny. Clients and partners are being notified of potential data exposure. 📊 *STOCKS:* SUNPHARMA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #CyberAttack

The Cyber Express18 May
High Impact

Sun Pharma eyes $12B Organon acquisition with financing plans

*Sun Pharma eyes $12B Organon acquisition with financing plans* — Sun Pharma is actively evaluating financing options for its proposed $12 billion acquisition of US-based Organon, marking a major strategic expansion. The deal, if completed, would be one of the largest in Indian pharma history. **$12 billion** underscores the scale and global ambition. 📊 *STOCKS:* SUNPHARMA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Acquisition

Siliconindia6 May
High Impact

Promoters of 5 stocks increase pledge up to 20%

*Promoters of 5 stocks increase pledge up to 20%* to add to your watchlist. A rise in promoter pledge up to **20%** signals potential financial stress or personal funding needs, often viewed as a red flag. While not immediate risk, elevated pledging may impact sentiment and stock stability. Monitor these stocks closely for downside volatility. 📊 *STOCKS:* SUNPHARMA, TATACONSUM, BHEL, NHPC, COALINDIA | 🏢 *SECTOR:* Risk | #LOWIMPACT #promoter_pledge

Trade Brains2 May
Low Impact

Rupee nears 95 on Sun Pharma deal, oil surge

*Rupee nears 95 on Sun Pharma deal, oil surge* — The Indian Rupee weakened to near **95 per USD**, pressured by a major **$4.5 billion Sun Pharma acquisition** and rising crude oil prices. The deal has sparked capital outflow concerns, while oil at **$90/barrel** adds import cost worries. Currency movement impacts F&O positions in export-heavy sectors. 📊 *STOCKS:* SUNPHARMA | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Rupee

Whalesbook29 Apr
Medium Impact

Financials

Quarterly Results

MetricDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
Revenue
₹15.5K Cr
▲7.2%
₹14.5K Cr
▲4.5%
₹13.9K Cr
▲6.9%
₹13.0K Cr
▼5.2%
₹13.7K Cr
▲2.9%
₹13.3K Cr
▲5.0%
₹12.7K Cr
▲5.6%
₹12.0K Cr
Op. Profit
₹4.9K Cr
▲9.3%
₹4.5K Cr
▲5.2%
₹4.3K Cr
▲15.8%
₹3.7K Cr
▼7.3%
₹4.0K Cr
▲1.8%
₹3.9K Cr
▲9.2%
₹3.6K Cr
▲18.9%
₹3.0K Cr
OPM
32.0%
▲3.2%
31.0%
▲0.0%
31.0%
▲6.9%
29.0%
▲0.0%
29.0%
▼3.3%
30.0%
▲3.4%
29.0%
▲16.0%
25.0%
Net Profit
₹3.4K Cr
▲8.2%
₹3.1K Cr
▲36.3%
₹2.3K Cr
▲6.5%
₹2.2K Cr
▼26.1%
₹2.9K Cr
▼4.1%
₹3.0K Cr
▲6.2%
₹2.9K Cr
▲7.6%
₹2.7K Cr
EPS (₹)
14.04
▲8.0%
13
▲36.8%
9.5
▲6.0%
8.96
▼26.0%
12.1
▼4.5%
12.67
▲7.2%
11.82
▲6.9%
11.06

Values in ₹ Cr · Source: Screener.in

Annual Profit & Loss

MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Revenue
₹58.5K Cr
▲11.2%
₹52.6K Cr
▲8.4%
₹48.5K Cr
▲10.5%
₹43.9K Cr
▲13.5%
₹38.7K Cr
▲15.4%
₹33.5K Cr
▲2.0%
₹32.8K Cr
▲13.0%
₹29.1K Cr
▲9.7%
₹26.5K Cr
▼16.1%
₹31.6K Cr
Expenses
₹40.7K Cr
▲8.7%
₹37.5K Cr
▲5.6%
₹35.5K Cr
▲10.1%
₹32.2K Cr
▲13.5%
₹28.4K Cr
▲13.5%
₹25.0K Cr
▼3.2%
₹25.9K Cr
▲14.0%
₹22.7K Cr
▲8.8%
₹20.9K Cr
▼2.9%
₹21.5K Cr
Op. Profit
₹17.7K Cr
▲17.3%
₹15.1K Cr
▲16.1%
₹13.0K Cr
▲11.7%
₹11.7K Cr
▲13.6%
₹10.3K Cr
▲21.1%
₹8.5K Cr
▲21.3%
₹7.0K Cr
▲9.5%
₹6.4K Cr
▲13.2%
₹5.6K Cr
▼44.3%
₹10.1K Cr
OPM
30.0%
▲3.4%
29.0%
▲7.4%
27.0%
▲0.0%
27.0%
▲0.0%
27.0%
▲8.0%
25.0%
▲19.0%
21.0%
▼4.5%
22.0%
▲4.8%
21.0%
▼34.4%
32.0%
Other Income
₹664 Cr
▼54.0%
₹1.4K Cr
▲66.9%
₹865 Cr
▲88.5%
₹459 Cr
▲113.1%
₹-3.5K Cr
▼1.6%
₹-3.4K Cr
▼1002.9%
₹382 Cr
▲248.1%
₹-258 Cr
▼91.1%
₹-135 Cr
▼122.1%
₹610 Cr
Interest
₹339 Cr
▲46.8%
₹231 Cr
▼2.9%
₹238 Cr
▲38.4%
₹172 Cr
▲35.4%
₹127 Cr
▼9.9%
₹141 Cr
▼53.5%
₹303 Cr
▼45.4%
₹555 Cr
▲7.1%
₹518 Cr
▲29.5%
₹400 Cr
Depreciation
₹2.9K Cr
▲14.1%
₹2.6K Cr
▲0.7%
₹2.6K Cr
▲1.1%
₹2.5K Cr
▲18.0%
₹2.1K Cr
▲3.1%
₹2.1K Cr
▲1.3%
₹2.1K Cr
▲17.1%
₹1.8K Cr
▲16.9%
₹1.5K Cr
▲18.6%
₹1.3K Cr
PBT
₹15.1K Cr
▲9.9%
₹13.8K Cr
▲24.0%
₹11.1K Cr
▲17.9%
₹9.4K Cr
▲110.0%
₹4.5K Cr
▲60.1%
₹2.8K Cr
▼44.1%
₹5.0K Cr
▲31.5%
₹3.8K Cr
▲9.5%
₹3.5K Cr
▼61.5%
₹9.0K Cr
Tax %
24.0%
▲20.0%
20.0%
▲53.8%
13.0%
▲44.4%
9.0%
▼62.5%
24.0%
▲33.3%
18.0%
▲12.5%
16.0%
▲0.0%
16.0%
▼38.5%
26.0%
▲100.0%
13.0%
Net Profit
₹11.5K Cr
▲5.0%
₹11.0K Cr
▲14.1%
₹9.6K Cr
▲12.9%
₹8.5K Cr
▲151.2%
₹3.4K Cr
▲49.2%
₹2.3K Cr
▼45.5%
₹4.2K Cr
▲30.0%
₹3.2K Cr
▲26.2%
₹2.5K Cr
▼67.6%
₹7.8K Cr
EPS (₹)
47.84
▲5.0%
45.55
▲14.1%
39.91
▲13.0%
35.32
▲158.9%
13.64
▲12.7%
12.1
▼22.9%
15.69
▲41.2%
11.11
▲27.3%
8.73
▼69.9%
29.03
Div Payout
33.0%
▼5.7%
35.0%
▲2.9%
34.0%
▲3.0%
33.0%
▼54.8%
73.0%
▲17.7%
62.0%
▲148.0%
25.0%
▲0.0%
25.0%
▲8.7%
23.0%
▲91.7%
12.0%

Values in ₹ Cr · Source: Screener.in

Balance Sheet

ItemSep 2025Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Liabilities
Equity Capital
₹240 Cr
▲0.0%
₹240 Cr
▲0.0%
₹240 Cr
▲0.0%
₹240 Cr
▲0.0%
₹240 Cr
▲0.0%
₹240 Cr
▲0.0%
₹240 Cr
▲0.0%
₹240 Cr
▲0.0%
₹240 Cr
▲0.0%
₹240 Cr
Reserves
₹77.6K Cr
▲7.8%
₹72.0K Cr
▲13.5%
₹63.4K Cr
▲13.8%
₹55.8K Cr
▲16.7%
₹47.8K Cr
▲3.3%
₹46.2K Cr
▲2.7%
₹45.0K Cr
▲9.4%
₹41.2K Cr
▲8.1%
₹38.1K Cr
▲4.6%
₹36.4K Cr
Borrowings
₹5.2K Cr
▲120.8%
₹2.4K Cr
▼27.9%
₹3.3K Cr
▼52.5%
₹6.9K Cr
▲433.8%
₹1.3K Cr
▼66.7%
₹3.9K Cr
▼53.5%
₹8.3K Cr
▼20.9%
₹10.5K Cr
▲1.2%
₹10.4K Cr
▲5.6%
₹9.8K Cr
Other Liabilities
₹20.7K Cr
▲19.3%
₹17.3K Cr
▼5.8%
₹18.4K Cr
▲3.1%
₹17.8K Cr
▼12.9%
₹20.5K Cr
▲18.4%
₹17.3K Cr
▲18.3%
₹14.6K Cr
▲15.4%
₹12.7K Cr
▼18.8%
₹15.6K Cr
▲6.7%
₹14.6K Cr
Total Liabilities
₹1.0L Cr
▲12.8%
₹91.9K Cr
▲7.7%
₹85.3K Cr
▲5.7%
₹80.7K Cr
▲15.7%
₹69.8K Cr
▲3.2%
₹67.6K Cr
▼0.8%
₹68.2K Cr
▲5.6%
₹64.6K Cr
▲0.5%
₹64.3K Cr
▲5.2%
₹61.1K Cr
Assets
Fixed Assets
₹33.4K Cr
▲47.8%
₹22.6K Cr
▼2.8%
₹23.2K Cr
▼3.4%
₹24.1K Cr
▲6.2%
₹22.7K Cr
▲5.2%
₹21.6K Cr
▼5.7%
₹22.8K Cr
▲4.6%
₹21.8K Cr
▲15.8%
₹18.9K Cr
▲6.7%
₹17.7K Cr
CWIP
₹1.4K Cr
▼79.6%
₹6.6K Cr
▲24.1%
₹5.4K Cr
▲7.7%
₹5.0K Cr
▲286.4%
₹1.3K Cr
▼17.9%
₹1.6K Cr
▲28.4%
₹1.2K Cr
▼13.5%
₹1.4K Cr
▼42.8%
₹2.5K Cr
▼12.0%
₹2.8K Cr
Investments
₹19.5K Cr
▲6.5%
₹18.4K Cr
▲22.1%
₹15.0K Cr
▲1.4%
₹14.8K Cr
▲15.4%
₹12.8K Cr
▲33.7%
₹9.6K Cr
▼5.2%
₹10.1K Cr
▲28.3%
₹7.9K Cr
▲10.6%
₹7.1K Cr
▲499.2%
₹1.2K Cr
Other Assets
₹49.4K Cr
▲11.5%
₹44.3K Cr
▲6.3%
₹41.7K Cr
▲13.2%
₹36.8K Cr
▲11.7%
₹33.0K Cr
▼5.5%
₹34.9K Cr
▲2.7%
₹34.0K Cr
▲1.6%
₹33.4K Cr
▼6.7%
₹35.8K Cr
▼9.1%
₹39.4K Cr
Total Assets
₹1.0L Cr
▲12.8%
₹91.9K Cr
▲7.7%
₹85.3K Cr
▲5.7%
₹80.7K Cr
▲15.7%
₹69.8K Cr
▲3.2%
₹67.6K Cr
▼0.8%
₹68.2K Cr
▲5.6%
₹64.6K Cr
▲0.5%
₹64.3K Cr
▲5.2%
₹61.1K Cr

Values in ₹ Cr · Source: Screener.in

Cash Flow Statement

ItemMar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Operating CF
₹14.1K Cr
▲16.0%
₹12.1K Cr
▲144.7%
₹5.0K Cr
▼44.8%
₹9.0K Cr
▲45.6%
₹6.2K Cr
▼5.9%
₹6.6K Cr
▲198.5%
₹2.2K Cr
▼43.8%
₹3.9K Cr
▼44.8%
₹7.1K Cr
▲5.9%
₹6.7K Cr
Investing CF
₹-5.2K Cr
▼579.3%
₹-763 Cr
▲89.4%
₹-7.2K Cr
▼29.9%
₹-5.6K Cr
▼1465.1%
₹407 Cr
▲118.3%
₹-2.2K Cr
▼617.7%
₹-310 Cr
▲90.0%
₹-3.1K Cr
▲25.8%
₹-4.2K Cr
▼6.0%
₹-3.9K Cr
Financing CF
₹-7.9K Cr
▼17.8%
₹-6.7K Cr
▼382.4%
₹2.4K Cr
▲145.8%
₹-5.2K Cr
▲13.2%
₹-6.0K Cr
▼4.6%
₹-5.7K Cr
▼109.3%
₹-2.7K Cr
▼77.5%
₹-1.5K Cr
▲32.6%
₹-2.3K Cr
▼21.0%
₹-1.9K Cr
Net Cash Flow
₹983 Cr
▼78.9%
₹4.7K Cr
▲3953.9%
₹115 Cr
▲106.5%
₹-1.8K Cr
▼396.1%
₹596 Cr
▲143.0%
₹-1.4K Cr
▼64.2%
₹-844 Cr
▼14.7%
₹-736 Cr
▼220.5%
₹611 Cr
▼27.9%
₹848 Cr
Free Cash Flow
₹12.0K Cr
▲20.5%
₹10.0K Cr
▲244.2%
₹2.9K Cr
▼61.7%
₹7.5K Cr
▲48.1%
₹5.1K Cr
▼0.2%
₹5.1K Cr
▲628.5%
₹-966 Cr
▼148.0%
₹2.0K Cr
▼42.4%
₹3.5K Cr
▲4.1%
₹3.4K Cr

Values in ₹ Cr · Source: Screener.in

Key Ratios History

MetricMar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Debtor Days
91d
▲7.1%
85d
▼10.5%
95d
▼4.0%
99d
▲0.0%
99d
▼5.7%
105d
▼6.3%
112d
▲3.7%
108d
▲30.1%
83d
▼4.6%
87d
Inventory Days
348d
▲3.0%
338d
▼6.1%
360d
▲14.3%
315d
▼16.7%
378d
▲21.5%
311d
▼15.0%
366d
▲8.3%
338d
▲10.1%
307d
▼17.0%
370d
Days Payable
210d
▲8.2%
194d
▲0.0%
194d
▲22.8%
158d
▼5.4%
167d
▲17.6%
142d
▼26.0%
192d
▼17.9%
234d
▲18.8%
197d
▼4.8%
207d
Cash Conv. Cycle
228d
▼0.4%
229d
▼12.3%
261d
▲2.4%
255d
▼17.7%
310d
▲13.1%
274d
▼3.9%
285d
▲34.4%
212d
▲9.8%
193d
▼23.1%
251d
Working Capital Days
65d
▲18.2%
55d
▲37.5%
40d
▼14.9%
47d
▼7.8%
51d
▲0.0%
51d
▲64.5%
31d
▲200.0%
-31d
▼675.0%
-4d
▼110.8%
37d
ROCE
20.0%
▲17.6%
17.0%
▲6.3%
16.0%
▼5.9%
17.0%
▲30.8%
13.0%
▲30.0%
10.0%
▲0.0%
10.0%
▲0.0%
10.0%
▼50.0%
20.0%
▲11.1%
18.0%

Source: Screener.in · Lower days = better efficiency

Deep Dive Analysis

Option Chain
Strike-wise OI & IV
OI Analysis
PCR, buildup type
FII / DII
Institutional flows
Max Pain
Writer pain levels

About Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market.[1] It is the largest pharmaceutical company in India.[2]

Healthcare · Pharmaceuticals & Biotechnology

Related Analysis

Same Sector

ALKEM
Alkem Laboratories Limited
Neutral
APOLLOHOSP
Apollo Hospitals Enterprise Limited
Neutral
AUROPHARMA
Aurobindo Pharma Limited
Neutral
BIOCON
Biocon Limited
Neutral
CIPLA
Cipla Limited
Neutral

Frequently Asked Questions

What is Sun Pharmaceutical Industries Limited share price today?▾
Sun Pharmaceutical Industries Limited (SUNPHARMA) is currently trading at ₹1,783.1 on NSE, as of the last market session. Prices update daily after market close on MarketNetra.
Is Sun Pharmaceutical Industries Limited available in F&O (Futures & Options)?▾
Yes, Sun Pharmaceutical Industries Limited (SUNPHARMA) is part of the NSE F&O segment with a lot size of 350 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Sun Pharmaceutical Industries Limited 52-week high and low?▾
Sun Pharmaceutical Industries Limited's 52-week high is ₹1,917 and the 52-week low is ₹1,547. The current price of ₹1,783.1 is 7.0% below the 52W high.
What is Sun Pharmaceutical Industries Limited P/E ratio?▾
Sun Pharmaceutical Industries Limited's current P/E ratio is 34.4. This indicates the market is paying ₹34.4 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Sun Pharmaceutical Industries Limited options?▾
Sun Pharmaceutical Industries Limited options are traded on NSE with monthly expiry contracts (lot size: 350 shares). To trade SUNPHARMA options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.